Current data on familial Mediterranean fever

Joint Bone Spine

Volumn 78, Issue 2, 2011, Pages 111-114

  Koné Paut, Isabelle ^a   Hentgen, Véronique ^b   Touitou, Isabelle ^c  

^a BICÊTRE HOSPITAL   (France)

^b CENTRE HOSPITALIER DE VERSAILLES   (France)

^c HÔPITAL ARNAUD DE VILLENEUVE   (France)

Author keywords

Autoinflammatory diseases; Familial Mediterranean fever; IL 1 antagonists; Interleukin 1; Treatment

Indexed keywords

COLCHICINE; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; AMYLOIDOSIS; AUTOINFLAMMATORY DISEASE; DIARRHEA; DRUG MECHANISM; DRUG SAFETY; EDITORIAL; FAMILIAL MEDITERRANEAN FEVER; GENE MUTATION; GENE SEQUENCE; GENETIC ASSOCIATION; GENETIC SCREENING; HUMAN; INNATE IMMUNITY; RECOMMENDED DRUG DOSE;

CASPASE 1; COLCHICINE; CYTOSKELETAL PROTEINS; FAMILIAL MEDITERRANEAN FEVER; HUMANS; INTERLEUKIN-1BETA; MEDITERRANEAN REGION; MUTATION; PREVALENCE; TREATMENT OUTCOME; TUBULIN MODULATORS;

EID: 79952246123     PISSN: 1297319X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jbspin.2010.09.021     Document Type: Editorial

References (25)

1. Touitou I., Koné-Paut I. Auto-inflammatory diseases. Best Pract Res Clin Rheumatol 2008, 22:811-829.
2. Touitou I., Lesage S., McDermott M., et al. Infevers: an evolving mutation database for auto-inflammatory syndromes. Hum Mutat 2004, 24:194-198.
3. Bernot A., Da Silva C., Petit J.L., et al. Non-founder mutations in the MEFV gene establish this gene as the cause of familial Mediterranean fever (FMF). Hum Mol Genet 1998, 7:1317-1325.
4. Ancient missense mutations in a new member of the RoRet gene family are likely to cause familial Mediterranean fever. Cell 1997, 90:797-807. The International FMF Consortium.
5. Centola M., Wood G., Frucht D.M., et al. The gene for familial Mediterranean fever, MEFV, is expressed in early leukocyte development and is regulated in response to inflammatory mediators. Blood 2000, 95(3):223-231.
6. Mansfield E., Chae J.J., Komarow H.D., et al. The familial Mediterranean fever protein, pyrin, associates with microtubules and colocalizes with actin filaments. Blood 2001, 98:851-859.
7. Chae J.J., Aksentijevich I., Kastner D.L. Advances in the understanding of familial Mediterranean fever and possibilities for targeted therapy. Br J Haematol 2009, 146:467-478.
8. Ben-Chetrit E., Touitou I. Familial Mediterranean fever in the world. Arthritis Rheum 2009, 63(10):1447-1453.
9. Chae J.J., Wood G., Masters S.L., et al. The B30.2 domain of pyrin, the familial Mediterranean fever protein, interacts directly with caspase-1 to modulate IL-1beta production. Proc Natl Acad Sci U S A 2006, 103:9982-9987.
10. Dodé C., Pêcheux C., Cazeneuve C., et al. Mutations in the MEFV gene in a large series of patients with a clinical diagnosis of familial Mediterranean fever. Am J Med Genet 2000, 92:241-246.
11. Sohar E., Gafni J., Pras M., et al. Familial Mediterranean fever. A survey of 470 cases and review of the literature. Am J Med 1967, 43:227-253.
12. Gershoni-Baruch R., Brik R., Zacks N., et al. The contribution of genotypes at the MEFV and SAA1 loci to amyloidosis and disease severity in patients with familial Mediterranean fever. Arthritis Rheum 2003, 48:1149-1155.
13. Lidar M., Kedem R., Berkun Y., et al. Familial Mediterranean fever in Ashkenazi Jews: the mild end of the clinical spectrum. J Rheumatol 2010, 37:422-425.
14. Sohar E, Gafni G, Pras M. Tel Hashomer key to severity scores for FMF. In: Sohar E, Gafni G, Pras M (Eds). Proceedings of the First International Conference on FMF. Freund Publishing House, London and Tel Aviv, 1997; 208.
15. Yalçi{dotless}nkaya F., Özen S., Özçakar B., et al. A new set of criteria for the diagnosis of familial Mediterranean fever in childhood. Rheumatology 2009, 48:395-398.
16. Livneh A., Langevitz P., Zemer D., et al. Criteria for the diagnosis of familial Mediterranean fever. Arthritis Rheum 1997, 40:1879-1885.
17. Lachmann H.J., Sengül B., Yavuzşen T.U., et al. Clinical and sub-clinical inflammation in patients with familial Mediterranean fever and in heterozygous carriers of MEFV mutations. Rheumatology (Oxford) 2006, 45:746-750.
18. Koné-Paut I., Hentgen V., Guillaume S., et al. The clinical spectrum of 94 patients carrying a single MEFV allele. Rheumatology (Oxford) 2009, 48:840-842.
19. Kallinich T., Haffner D., Niehues T., et al. Colchicine use in children and adolescents with familial Mediterranean fever: literature review and consensus statement. Pediatrics 2007, 119:e474-e483.
20. Fonnesu C., Cerquaglia C., Giovinale M., et al. Familial Mediterranean Fever: a review for clinical management. Joint Bone Spine 2009, 76:227-233.
21. Pétrilli V., Martinon F. The inflammasome, autoinflammatory diseases, and gout. Joint Bone Spine 2007, 74:571-576.
22. Belkhir R., Moulonguet-Doleris L., Hachulla E., et al. Treatment of familial Mediterranean fever with anakinra. Ann Intern Med 2007, 146:825-826.
23. Moser C., Pohl G., Haslinger I., et al. Successful treatment of familial Mediterranean fever with Anakinra and outcome after renal transplantation. Nephrol Dial Transplant 2009, 24:676-678.
24. Roldan R., Ruiz A.M., Miranda M.D., et al. Anakinra: new therapeutic approach in children with Familial Mediterranean Fever resistant to colchicine. Joint Bone Spine 2008, 75:504-505.
25. Moltó A., Olivé A. Anti-IL-1 molecules: new comers and new indications. Joint Bone Spine 2010, 77:102-107.